Tri.Fr 2 years outcomes presented at ACC 2026
The Tri.Fr trial delivered sustainable evidence . Together with the Triluminate Pivotal trial , the results confirm TriClip TEER as the only TTVI therapy with consistent evidence demonstrating both symptomatic improvement and reduction in HFH
LEARN MORE:
Related Resources
Valvular Heart Disease Guidelines at a Glance
Demonstrated Outcomes. Life-Changing Intervention
Reduced HF Hospitalisation. Improved Quality of Life
Immediate Relief. Durable Benefits
Navitor 5-years data from CRT
Tendyne expanded clinical study | PCR LV 2025
EXPAND G4 clinical data release | PCR LV 2025